Phase II trial of imatinib mesylate in patients with metastatic melanoma.

British Journal of Cancer
K B KimV G Prieto

Abstract

Metastatic melanoma cells express a number of protein tyrosine kinases (PTKs) that are considered to be targets for imatinib. We conducted a phase II trial of imatinib in patients with metastatic melanoma expressing at least one of these PTKs. Twenty-one patients whose tumours expressed at least one PTK (c-kit, platelet-derived growth factor receptors, c-abl, or abl-related gene) were treated with 400 mg of imatinib twice daily. One patient with metastatic acral lentiginous melanoma, containing the highest c-kit expression among all patients, had dramatic improvement on positron emission tomographic scan at 6 weeks and had a partial response lasting 12.8 months. The responder had a substantial increase in tumour and endothelial cell apoptosis at 2 weeks of treatment. Imatinib was fairly well tolerated: no patient required treatment discontinuation because of toxicity. Fatigue and oedema were the only grade 3 or 4 toxicities that occurred in more than 10% of the patients. Imatinib at the studied dose had minimal clinical efficacy as a single-agent therapy for metastatic melanoma. However, based on the characteristics of the responding tumour in our study, clinical activity of imatinib, specifically in patients with melanoma with...Continue Reading

References

Mar 11, 1991·Proceedings of the National Academy of Sciences of the United States of America·J G BeitzA R Frackelton
Mar 1, 1989·Controlled Clinical Trials·R Simon
Mar 28, 1995·Proceedings of the National Academy of Sciences of the United States of America·E BuchdungerN B Lydon
Dec 3, 1999·The International Journal of Biochemistry & Cell Biology·L K Ashman
Jan 5, 2000·The Journal of Clinical Investigation·B J Druker, N B Lydon
Apr 6, 2001·Blood·K OkudaJ D Griffin
Nov 14, 2001·Lancet·A T van OosteromUNKNOWN European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
Jun 18, 2002·Nature·Helen DaviesP Andrew Futreal
Sep 6, 2003·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J VerweijO S Nielsen
Sep 26, 2003·Journal of Cutaneous Pathology·Steven S ShenVictor G Prieto
Dec 4, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael C HeinrichJonathan A Fletcher
Apr 23, 2005·British Journal of Cancer·S UgurelD Schadendorf
Aug 16, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John A CurtinBoris C Bastian

❮ Previous
Next ❯

Citations

Mar 28, 2013·Journal of Skin Cancer·Farid Menaa
Feb 11, 2014·Journal of the National Cancer Institute·Klaus G GriewankRajmohan Murali
Aug 13, 2009·Molecular Cancer Therapeutics·Scott E WoodmanMichael A Davies
Aug 11, 2010·Oncogene·M A Davies, Y Samuels
Jun 7, 2011·JAMA : the Journal of the American Medical Association·Richard D CarvajalGary K Schwartz
Mar 2, 2013·Therapeutic Advances in Medical Oncology·Muhammad KhattakJames Larkin
Nov 3, 2011·Expert Reviews in Molecular Medicine·Ivan PachecoVictor Tron
Sep 1, 2009·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Carlos A Torres-CabalaDoina Ivan
Oct 19, 2011·Journal of Skin Cancer·Daniela Göppner, Martin Leverkus
May 20, 2009·Future Oncology·Aaron S Mansfield, Svetomir N Markovic
Mar 6, 2012·BMC Medicine·Laura FinnRichard W Joseph
May 31, 2012·The Journal of Laryngology and Otology·M C Brown, R J Casasola
May 25, 2012·Expert Opinion on Therapeutic Targets·Helena PópuloJosé Manuel Lopes
Mar 15, 2014·Expert Opinion on Biological Therapy·Sara TomeiDavide Bedognetti
Aug 11, 2012·Expert Opinion on Investigational Drugs·Diwakar Davar, John Munn Kirkwood
Sep 21, 2013·Expert Opinion on Investigational Drugs·Matias E Valsecchi, Takami Sato
Jun 19, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F Stephen HodiDavid E Fisher
Aug 14, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Richard D Carvajal
Aug 14, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Megan Lyle, Georgina V Long
Apr 3, 2010·Translational Oncology·Francesca BelleudiMaria Rosaria Torrisi
Apr 22, 2017·Journal for Immunotherapy of Cancer·Matthew J ReilleyDavid S Hong
Feb 8, 2018·Molecular Diagnosis & Therapy·Anna EisensteinRhoda M Alani
Jun 17, 2011·Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology·M B KarpovaR Dummer
Mar 11, 2015·Therapeutic Advances in Medical Oncology·Colin R LindsayAshita Waterston
Jul 12, 2013·Clinical Medicine Insights. Oncology·April K S Salama
Dec 20, 2014·The Cochrane Database of Systematic Reviews·Thrasivoulos TzellosZoe Apalla
Jul 1, 2009·Therapeutic Advances in Medical Oncology·D K Wilkins, P D Nathan
Mar 30, 2011·International Journal of Cancer. Journal International Du Cancer·Andree YeramianRosa M Martí
Aug 23, 2011·Journal of Surgical Oncology·Vernon K SondakRagini Kudchadkar
Dec 3, 2010·The Journal of Pathology·Cristina R Antonescu
Jan 25, 2019·Current Treatment Options in Oncology·Kenjiro Namikawa, Naoya Yamazaki
Aug 5, 2009·The American Journal of Dermatopathology·Julie M WuElizabeth A Montgomery
Mar 5, 2019·World Journal of Surgery·James P TaylorJonathan E Efron
Apr 4, 2009·Targeted Oncology·Florence Duffaud, Axel Le Cesne
Apr 12, 2011·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Michelle L WallanderJoseph A Holden
Feb 22, 2012·Archives of Dermatological Research·Francesco Spagnolo, Paola Queirolo
Nov 12, 2010·International Journal of Clinical Oncology·Miki ItohYasuhisa Shinomura
Jun 8, 2012·Surgery Today·Masaki WakasugiToshirou Nishida
Oct 21, 2010·Cancer·Michael A DaviesAgop Bedikian
May 11, 2011·Expert Review of Anticancer Therapy·Glen M Boyle
May 21, 2011·Pigment Cell & Melanoma Research·Ruixia LiangBrian P Rubin
Mar 29, 2012·The Cancer Journal·Melissa Ann Wilson, Katherine L Nathanson
Mar 29, 2012·The Cancer Journal·Michael A Postow, Richard D Carvajal
Jan 10, 2013·Current Opinion in Oncology·Lu Si, Jun Guo
Dec 20, 2012·Expert Review of Anticancer Therapy·Emma Dean, Paul Lorigan

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsies
biopsy

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.